anemia%20-%20iron-deficiency%20(pediatric)
ANEMIA - IRON-DEFICIENCY (PEDIATRIC)

Iron deficiency (ID) is the most common nutritional deficiency in children & reportedly 3x more common than iron-deficiency anemia, but does not always develop into anemia.

Neonates & children may have delayed growth & development; adolescents may show decrements of learning such as behavioral abnormalities.

Iron-deficiency anemia is the most advanced stage of iron deficiency resulted from a protracted imbalance between iron intake & demand.

Characterized by low hemoglobin & hematocrit levels, reduction or depletion of iron stores, low serum iron levels & decreased transferrin saturation.

Drug Information
Iberet Folic-500
ascorbic acid + calcium pantothenate + cyanocobala...

Indication: Prevention & treatment of Fe-deficiency anemia & prevention of folate deficiency.

Indication: Fe deficiency when clinically needed to deliver Fe rapidly to Fe stores, in patients who cannot tolerate or ar...

Indication: Fe deficiency in adults when oral Fe prep cannot be used due to intolerance or in case of demonstrated lack of...

Indication: Fe deficiency anaemia where there is clinical need for rapid Fe supply, in patients who cannot tolerate or are...

Indication: Fe deficiency w/ & w/o anaemia. Prophylaxis of Fe deficiency during pregnancy.

Indication: Fe deficiency w/ or w/o anaemia. Prophylactic therapy of Fe deficiency to cover the recommended daily dietary ...

Indication: Fe deficiency w/ or w/o anaemia. Prevention of Fe & folic acid deficiency before, during & after pregn...

Indication: Fe deficiency w/ or w/o anemia. Prophylactic therapy of Fe deficiency during pregnancy.

Sangobion Complete
copper sulfate + ferrous gluconate + folic acid + ...

Indication: Fe-deficiency anaemia; haemorrhagic anaemia of traumatic or endogenous origin; anaemia during pregnancy, growt...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.